Pursuant to Article 25(4) of the Law on Companies of the Republic of Lithuania, we hereby inform you about the supplementation, on the initiative and decision of the Board of AUGA group, AB under restructuring (legal entity code 126264360, registered office at Konstitucijos Ave. 21C, Vilnius, hereinafter – the Company), of the draft resolutions proposed for the Extraordinary General Meeting of Shareholders of the Company (hereinafter – the Meeting).
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.
AUGA group, AB entity under restructuring (code 126264360, registered office at Konstitucijos pr. 21C, Vilnius, hereinafter referred to as the “Company”), by the initiative and decision of the Board, is convening a General meeting of shareholders on August 12, 2025, at 10:00 a.m., where the Company’s shareholders will vote on the approval of the Company’s draft restructuring plan, hereinafter referred to as the “Meeting”.